AVI Products India Limited Overview
AVI Products India Limited is a 37-year-old, BSE-listed micro-entity. It spent most of the last decade as an asset-light trader of dental consumables and equipment, selling through its own e-commerce site Dentaldeal.in. Alongside that it ran IFRUIT, a small franchise-led ice-cream and waffle format. Peak revenue was only ₹4.85 crore (FY2024). Operating revenue fell to zero by the June 2026 quarter as the founding Vora family wound the business down ahead of selling control. In February 2026 PPMS Real Estates LLP, a Mumbai real-estate platform with experience in Slum Rehabilitation Authority (SRA) redevelopment, agreed to acquire control. It completed a mandatory open offer at ₹33 per share and now owns 62.83%. Shareholders have authorised a pivot into real estate, healthcare, chemicals and IT, plus ₹100 crore of borrowing capacity. The listed entity is now best characterised as a clean, low-debt listed shell. Its future value depends almost entirely on what the new promoter injects into it, and on what governance safeguards come with that.
The company's own description
The company's filings consistently describe it as trading dental products and equipment. The FY2025 directors' report (36th Annual Report) states that the company is in the trading of dental products and equipment. The FY2024 annual report gives a broader business description: AVI acts across India and globally as an advisor, consultant, planner, trainer, intermediary, broker, publisher, developer, agent, contractor and service provider in the dental, medical, diagnostic and healthcare sectors (Screener.in, citing FY2024 Annual Report p.9).
The company summary on IndiaInfoline, derived from the company's corporate profile, makes these points:
-
AVI began as a trader of chemicals and an e-commerce operator.
-
It moved into dental and healthcare distribution, and into food and beverage franchising under IFRUIT.
-
It began marketing Indian-made endodontic files. It used digital marketing to reach dentists directly and passed on the dealer margin it bypassed.
-
After the change in management, the object clause was amended on 28 May 2026 so the company can undertake real-estate business from FY2027 onwards.
Independent characterisation
AVI historically had two businesses.
Dental e-commerce and trading (Dentaldeal.in). This was a B2B and B2C online catalogue selling third-party and private-label dental consumables and small equipment to dental clinics and practitioners across India. The model was pure trading:
-
Goods were bought from manufacturers and importers and resold online.
-
Revenue was recognised on product sale, and gross margins were roughly 33–39% (FY2022–FY2025, StockAnalysis.com).
-
Value-chain position was downstream distribution and retail. There was no manufacturing, no proprietary technology and no recurring subscription income.
Food & Beverages (IFRUIT). IFRUIT began as company-run ice-cream parlours in Mumbai using imported machinery. It then shifted to a franchise model. Revenue came from three sources:
-
franchise fees,
-
sales of ice-cream machines (stir-fried "roll" ice-cream pans, hard ice-cream, soft-serve and popsicle machines) to franchisees,
-
sales of ingredients and consumables.
The company reported more than 40 outlets, offered five franchise formats, and stated an ambition to reach 200 franchises within two years. That target has not been reported as achieved in any later filing reviewed.
Revenue model mix. No numerical split is disclosed in the sources reviewed. Qualitatively:
-
Product trading (dental) was the dominant line, since the annual reports describe the company as a dental trader.
-
Franchise fees and machine sales (F&B) were a minority.
-
There was no subscription, licensing or service revenue of significance.
Customer types and end-markets. Customers were dental practitioners, dental clinics and hospitals across India, plus IFRUIT franchisees (small entrepreneurs in tier-2 and tier-3 cities). The end-markets were Indian dental consumables and equipment, and Indian QSR/dessert retail. The FY2025 directors' report recorded nil foreign-currency expenditure, so operations were domestic.
Current state (October 2026).
-
Operating revenue was zero in Q1 FY2027 (quarter ended 30 June 2026). Total income of ₹7.80 lakh came entirely from other income.
-
Inventories fell to ₹123.22 lakh at 31 March 2026, and property, plant & equipment fell to ₹14.59 lakh.
-
The 37th AGM approved the sale of company-owned assets to the outgoing promoters and a director.
-
The legacy businesses are therefore being run off.
-
The new object clause covers real-estate development and construction, healthcare services and medical tourism, internet services, and chemical and food manufacturing (Whalesbook summary of the postal ballot outcome, 30 May 2026). No new business revenue has been reported yet.
Strategy
Stated strategy
There is no investor-day or strategy document. Strategic intent has to be inferred from shareholder resolutions and board actions:
-
Pivot to real estate. The object clause was amended (approved 30 May 2026; IndiaInfoline records the change as dated 28 May 2026) so the company can carry on real-estate business from FY2027. The new CIN carries the real-estate NIC code (68200). The new MD's background is in SRA redevelopment, joint ventures and valuation.
-
Broad diversification optionality. The objects also cover chemicals and petrochemicals, healthcare and medical tourism, IT consultancy, internet services, food manufacturing and e-commerce (Whalesbook, 30 May 2026).
-
Balance-sheet capacity. Shareholders approved:
-
borrowing powers of up to ₹100 crore under Section 180(1)(c),
-
creation of charges on assets under Section 180(1)(a),
-
loans, guarantees and investments of up to ₹100 crore under Sections 185 and 186. That is about 19x the FY2026 net worth of ₹5.16 crore.
-
-
Related-party ecosystem. Material related-party transactions were approved with 45 entities for FY2027, capped at ₹25 crore per entity. Activities covered include real estate, consultancy and investments. Named counterparties include Paradigm Realty Pvt Ltd and PPMS Real Estates LLP. The theoretical aggregate ceiling is ₹1,125 crore (45 × ₹25 crore).
-
Legacy run-off. Operating revenue was zero in Q1 FY2027, and assets are being sold to the outgoing promoters and a director (37th AGM approval).
Medium-term financial targets or guidance: none disclosed. Historically, management talked of scaling IFRUIT to 200 franchises within two years; that target is now superseded.
Initiatives in the last 24 months
| Date | Initiative | Detail | Status |
|---|---|---|---|
| Jan 2026 | Governance refresh | New independent and non-executive directors, new CS, auditor and secretarial auditor appointments | Superseded by the April 2026 reconstitution |
| Feb–Jun 2026 | Change of control | Acquisition by PPMS Real Estates LLP plus mandatory open offer | Completed 10 June 2026 |
| Apr 2026 | Registered office move | Vasai to Khar (West), Mumbai | Effective 23 April 2026 |
| May 2026 | Object-clause amendment | Real estate and diversified objects | Approved |
| May 2026 | ₹100 crore borrowing and loan/investment limits | Sections 180, 185, 186 | Approved; no borrowing drawn as of FY2026 (borrowings ₹0.01 crore) |
| May 2026 | Material RPT framework | 45 entities, ₹25 crore each, FY2027 | Approved; promoter group abstained |
| Jun–Sep 2026 | Legacy asset disposal | Cars sold to Avinash Vora for ₹5,23,660; broader asset sale to promoters and director | Car sale due by 31 October 2026; broader sale approved 24 September 2026 |
| Aug 2026 | New MD | Parthh K. Mehta appointed for 5 years | Approved at AGM |
ESG or sustainability commitments: none disclosed. Cost programmes: none formally announced, although quarterly expenses fell from ₹102.18 lakh (Q1 FY2026) to ₹27.67 lakh (Q1 FY2027).
Products & Services
Pricing, launch years and technical specifications for individual SKUs are not publicly disclosed. The catalogue below is compiled from company descriptions reproduced by Simply Wall St, Investing.com and IndiaInfoline, and from Screener.in's annual-report extracts.
E-commerce & Trading segment (Dentaldeal.in)
| Product line | Description / capability | Target customer | Pricing model |
|---|---|---|---|
| Endo-motors | Motorised handpieces that drive rotary root-canal files | Endodontists, general dentists | Unit sale; price not disclosed |
| Intra-oral cameras | Chairside imaging devices for patient communication and records | Dental clinics | Unit sale; not disclosed |
| LED light-curing machines | Units that polymerise composite restorations | General dentists | Unit sale; not disclosed |
| Autoclave products | Steam sterilisers for instruments | Clinics, hospitals | Unit sale; not disclosed |
| UV chambers | Ultraviolet storage and disinfection cabinets for instruments | Clinics | Unit sale; not disclosed |
| Dental X-ray developers & fixers | Film-processing chemicals, a legacy of the "Photochem" heritage | Clinics using film radiography | Consumable; not disclosed |
| Composite filling materials | Tooth-coloured restorative resins | General dentists | Consumable; not disclosed |
| Root-canal (endodontic) files | Indian-made files, described by the company as a fast-moving product and promoted via digital marketing | Endodontists, general dentists | Consumable; not disclosed |
| Orthodontic materials | Brackets, wires and accessories (specific items not detailed) | Orthodontists | Consumable; not disclosed |
| Dental chemicals — Etchant | Acid etching gel for bonding | General dentists | Consumable; not disclosed |
| Dental chemicals — Root Help | Endodontic chemical (named product; composition not disclosed) | Endodontists | Consumable; not disclosed |
| Dental chemicals — Root Cal | Root-canal medicament, likely calcium-hydroxide based (composition not disclosed) | Endodontists | Consumable; not disclosed |
| Dental chemicals — Desensitizer | Dentine desensitising agent | General dentists | Consumable; not disclosed |
Flagship offering: Indian-made endodontic files sold direct to practitioners, as highlighted in the company profile.
Food & Beverages segment (IFRUIT)
| Product / format | Description | Target customer | Pricing model |
|---|---|---|---|
| Ice-cream rolls ("rollies") | Stir-fried / cold-plate rolled ice-cream | Consumers via franchise outlets | Retail; not disclosed |
| Ice-cream candies / kulfis | Frozen novelty items | Consumers | Retail; not disclosed |
| Sorbets and gelatos | Frozen desserts | Consumers | Retail; not disclosed |
| Juices | Fresh beverages | Consumers | Retail; not disclosed |
| Sundaes and fusions | Composite desserts | Consumers | Retail; not disclosed |
| Frosties, smoothies, milkshakes | Blended beverages | Consumers | Retail; not disclosed |
| Belgian waffles | Waffle desserts | Consumers | Retail; not disclosed |
| Single-pan stir-fried ice-cream machine | Equipment for rolled ice-cream | Franchisees | Equipment sale; not disclosed |
| Small hard ice-cream machine | Batch freezer | Franchisees | Equipment sale; not disclosed |
| Table-top soft-serve machine | Soft-serve dispenser | Franchisees | Equipment sale; not disclosed |
| Popsicle / candy machine | Stick novelty maker | Franchisees | Equipment sale; not disclosed |
| IFRUIT franchise packages | Five franchise models for different budgets; more than 40 outlets opened | Small entrepreneurs, tier-2/3 towns | Franchise fee plus equipment; fees not disclosed |
| Quick Service Restaurant (QSR) chain (planned) | Company stated plans to open a QSR chain for fast food | Consumers | No evidence of execution in the filings reviewed |
Prospective portfolio (post-pivot)
The amended object clause (approved 30 May 2026) permits:
-
real-estate development and construction,
-
real-estate consultancy,
-
healthcare services and medical tourism,
-
internet services and IT consultancy,
-
chemicals and petrochemicals,
-
food manufacturing,
-
e-commerce.
No products, projects or services under these objects have been announced as of 20 October 2026.
Financial Narrative
All figures are standalone and in ₹ crore unless stated. The primary source is Screener.in (C-MOTS data compiled from BSE annual and quarterly filings), cross-checked against StockAnalysis.com (₹ million), the FY2025 directors' report (IIFL) and FY2026 audited results (ScanX summary of the 30 May 2026 BSE filing). EBITDA is approximated as operating profit before other income, as Screener defines it. Ratios marked "computed" were calculated by the analyst from these figures.
Income statement
Notes: - FY2022 revenue growth is computed against FY2021 revenue of ₹2.38 crore.
-
No diluted EPS distinct from basic is disclosed, and there are no outstanding convertibles in the sources reviewed.
-
FY2025 reconciliation: the directors' report shows profit before tax of ₹718 thousand and profit after tax of ₹537 thousand, against FY2024 figures of ₹3,262 thousand and ₹2,550 thousand. This matches Screener's ₹0.08 crore and ₹0.05 crore.
Margin profile
Revenue CAGR (computed):
-
FY2022 → FY2025: +12.1% a year (₹3.34 crore to ₹4.70 crore).
-
FY2022 → FY2026: −23.1% a year (₹3.34 crore to ₹1.17 crore).
-
Screener reports 5-year compounded sales growth of −13% and 3-year growth of −31%.
Commentary. Between FY2021 and FY2024 the company was a functioning micro-distributor. Revenue grew from ₹2.38 crore to ₹4.85 crore, helped by post-COVID normalisation of dental practice volumes and IFRUIT franchise additions. Gross margins in the 34–39% range are healthy for a distributor and reflect private-label and direct-to-dentist pricing. However, operating expenses consumed almost all of that gross profit, so EBITDA margins never exceeded 8.3%. The business had no operating leverage: fixed costs (staff, marketing, platform) were large relative to a revenue base of ₹3–5 crore.
Inflection points:
-
FY2024. Depreciation more than doubled, from ₹0.06 crore to ₹0.14 crore, after fixed assets rose to ₹1.44 crore. Capex was about ₹1.00 crore, apparently on vehicles, equipment and outlet assets.
-
FY2025. Revenue was flat, but the operating margin collapsed to 0.85% as expenses rose to ₹4.66 crore. Other income of ₹0.24 crore, mainly interest on cash, kept the year profitable.
-
FY2026. The legacy businesses were wound down. Quarterly revenue fell from ₹0.58 crore (June 2025) to ₹0.08 crore (March 2026). Gross profit turned negative because cost of revenue (₹15.77 million) exceeded revenue (₹11.80 million). This is consistent with inventory liquidation or write-downs. The net loss of ₹1.94 crore wiped out about 27% of opening net worth.
Quarterly trajectory (8 quarters plus latest)
Source: Screener.in. The Q1 FY2027 detail (Capital Market, ScanX, 5–6 August 2026) is:
-
income from operations: nil
-
other income: ₹7.80 lakh
-
total expenses: ₹27.67 lakh
-
loss before tax: ₹19.87 lakh
-
tax credit: ₹2.01 lakh
-
net loss: ₹17.86 lakh, against a loss of ₹39.62 lakh in Q1 FY2026
Balance sheet
Additional FY2025 and FY2026 detail from the audited balance sheet (ScanX summary of the 30 May 2026 BSE filing; ₹ lakh):
A key observation on asset quality. At 31 March 2026, current assets were ₹507.12 lakh. Of that:
-
inventory was ₹123.22 lakh,
-
receivables were ₹20.34 lakh,
-
cash was ₹3.37 lakh.
That leaves about ₹360 lakh (≈₹3.6 crore) of "other current assets," roughly 69% of total assets. Their composition is not disclosed in the summaries reviewed; they could be loans and advances, deposits or other receivables. Cash fell by ₹315.63 lakh during FY2026 while operating cash flow was −₹311.25 lakh. This suggests cash was converted into advances or other current assets classified within operating activities. Identifying the nature and counterparties of these ₹3.6 crore of assets is the single most important diligence item for any investor.
Cash flow
In FY2026, the investing inflow of ₹81.93 lakh came largely from sales of property, plant and equipment. The financing outflow of ₹86.31 lakh included repayment of ₹81.00 lakh of short-term borrowings (ScanX summary of the FY2026 audited cash flow).
Commentary. Free cash flow was negative in every year from FY2022 to FY2026, totalling about −₹4.9 crore. The equity raises of FY2022 and FY2024 (financing inflows of ₹2.09 crore and ₹2.48 crore, mostly preferential capital) funded both the operating cash burn and the FY2024 capex. The company has never paid a dividend (Screener shows 0% payout every year since FY2015).
Ratio analysis
Further notes: - Current ratio (computed): 7.3x at 31 March 2025 and 82.5x at 31 March 2026. Earlier years are not disclosed in the sources reviewed.
-
Net debt / EBITDA is not meaningful: the company held net cash in FY2025 and FY2026 and EBITDA was negative in FY2026.
-
ROIC is not separately disclosed; ROCE is the closest proxy.
-
Screener reports last-year ROE of −23.3%, presumably on a different denominator. MarketInOut reports trailing ROE of −28.71% and ROIC of −44.63%.
Commentary.
Inventory days: These averaged 240–285 days, which is very high even for dental consumables and points to slow-moving stock.
Returns: Combined with thin operating margins, the long inventory cycle kept ROCE in single digits even in the best years.
Leverage: This has never been a concern. The ₹0.82 crore of FY2025 short-term borrowings was repaid in FY2026.
Valuation basis: The working-capital-days figure of 1,553 for FY2026 is an artefact of collapsing revenue against a balance sheet still holding ₹5 crore of current assets. Analytically, the entity is now valued on its net assets plus control/option value, not on earnings.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains | Products / services |
|---|---|---|
E-commerce & Trading | Dental and healthcare products sold through Dentaldeal.in and direct trading | Endo-motors, intra-oral cameras, LED curing lights, autoclaves, UV chambers, X-ray developers and fixers, composites, endodontic files, orthodontic materials, dental chemicals |
Food & Beverages | IFRUIT franchise brand | Ice-cream rolls, kulfis and candies, sorbets, gelato, juices, sundaes, shakes and smoothies, Belgian waffles; ice-cream machines sold to franchisees |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue from operations (INR Cr) | 4.85 | 4.70 | 1.17 |
YoY growth (%) | 34.3 | -3.1 | -75.1 |
Operating profit before other income (INR Cr) | 0.26 | 0.04 | -1.48 |
Operating margin (%) | 5.36 | 0.85 | -126.50 |
Profit before tax (INR Cr) | 0.32 | 0.08 | -1.92 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 3.34 | 3.61 | 4.85 | 4.70 | 1.17 |
Revenue growth YoY (%) | 40.3 | 8.1 | 34.3 | -3.1 | -75.1 |
Gross profit (INR Cr; StockAnalysis) | 1.26 | 1.41 | 1.64 | 1.56 | -0.40 |
Total expenses excl. D&A and interest (INR Cr) | 3.12 | 3.31 | 4.59 | 4.66 | 2.65 |
EBITDA / operating profit (INR Cr) | 0.22 | 0.30 | 0.26 | 0.04 | -1.48 |
Other income (INR Cr) | 0.03 | 0.08 | 0.21 | 0.24 | -0.30 |
Interest (INR Cr) | 0.05 | 0.04 | 0.01 | 0.05 | 0.05 |
Depreciation (INR Cr) | 0.04 | 0.06 | 0.14 | 0.15 | 0.09 |
Operating income, StockAnalysis basis (INR Cr) | 0.18 | 0.23 | 0.21 | -0.09 | -2.06 |
Profit before tax (INR Cr) | 0.16 | 0.28 | 0.32 | 0.08 | -1.92 |
Tax rate (%) | 25.00 | 25.00 | 21.88 | 25.00 | 1.04 |
Net income (INR Cr) | 0.12 | 0.21 | 0.26 | 0.05 | -1.94 |
EPS basic, Screener (INR) | 0.46 | 0.81 | 0.79 | 0.15 | -5.87 |
EPS diluted (INR) | 0.46 | 0.81 | 0.79 | 0.15 | -5.87 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%; StockAnalysis) | 37.7 | 39.1 | 33.8 | 33.0 | -33.6 |
EBITDA / operating margin (%) | 6.59 | 8.31 | 5.36 | 0.85 | -126.50 |
Pre-tax margin (%; computed) | 4.79 | 7.76 | 6.60 | 1.70 | -164.10 |
Net margin (%; computed) | 3.59 | 5.82 | 5.36 | 1.06 | -165.81 |
Income Statement and Per-Share Data
| Metric | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | Mar-2026 | Jun-2026 |
|---|---|---|---|---|---|---|---|---|---|
Sales (INR Cr) | 1.06 | 0.89 | 1.13 | 1.63 | 0.58 | 0.19 | 0.33 | 0.08 | 0.00 |
Expenses (INR Cr) | 1.01 | 0.83 | 1.20 | 1.62 | 0.96 | 0.72 | 0.79 | 0.70 | 0.28 |
Operating profit (INR Cr) | 0.05 | 0.06 | -0.07 | 0.01 | -0.38 | -0.53 | -0.46 | -0.62 | -0.28 |
Other income (INR Cr) | 0.05 | 0.01 | 0.11 | 0.08 | 0.04 | 0.02 | 0.06 | 0.09 | 0.08 |
Profit before tax (INR Cr) | 0.05 | 0.02 | -0.03 | 0.03 | -0.40 | -0.55 | -0.44 | -0.55 | -0.20 |
Net profit (INR Cr) | 0.04 | 0.01 | -0.03 | 0.02 | -0.40 | -0.55 | -0.44 | -0.57 | -0.18 |
EPS (INR) | 0.12 | 0.03 | -0.09 | 0.06 | -1.21 | -1.66 | -1.33 | -1.72 | -0.54 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Equity share capital (INR Cr) | 2.58 | 2.58 | 3.31 | 3.31 | 3.31 |
Reserves / other equity (INR Cr) | 1.76 | 1.96 | 3.74 | 3.79 | 1.85 |
Total equity / net worth (INR Cr) | 4.34 | 4.54 | 7.05 | 7.10 | 5.16 |
Borrowings, total (INR Cr) | 0.02 | 0.01 | 0.26 | 0.82 | 0.01 |
Other liabilities (INR Cr) | 0.43 | 0.17 | 0.80 | 0.08 | 0.06 |
Total assets (INR Cr) | 4.79 | 4.72 | 8.11 | 8.00 | 5.23 |
Net fixed assets (INR Cr) | 0.45 | 0.58 | 1.44 | 1.36 | 0.15 |
Other assets incl. current (INR Cr) | 4.34 | 4.14 | 6.67 | 6.64 | 5.08 |
Goodwill & intangibles (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet (FY2025–FY2026)
| Line item (INR Lakh) | FY2025 | FY2026 |
|---|---|---|
Total assets | 799.48 | 523.51 |
Non-current assets | 143.09 | 16.39 |
Property, plant & equipment | not separately disclosed in summary | 14.59 |
Current assets | 656.39 | 507.12 |
Inventories | not separately disclosed in summary | 123.22 |
Trade receivables | not separately disclosed in summary | 20.34 |
Cash & cash equivalents | 319.00 | 3.37 |
Total current liabilities | 89.87 | 6.15 |
Equity share capital | 330.68 | 330.68 |
Other equity | 378.93 | 184.67 |
Liquidity & Coverage Ratios
| Metric | FY2025 | FY2026 |
|---|---|---|
Cash & equivalents (INR Cr) | 3.19 | 0.03 |
Total debt (INR Cr; short-term) | 0.82 | 0.01 |
Long-term debt (INR Cr) | 0 | 0 |
Net debt (INR Cr; negative = net cash) | -2.37 | -0.02 |
Working capital (INR Cr) | 5.67 | 5.01 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 0.10 | -0.62 | 0.31 | -0.77 | -3.11 |
Investing cash flow (INR Cr) | -0.09 | -1.51 | -0.90 | 0.14 | 0.82 |
Financing cash flow (INR Cr) | 2.09 | -0.06 | 2.48 | 0.50 | -0.86 |
Net cash flow (INR Cr) | 2.10 | -2.18 | 1.90 | -0.14 | -3.16 |
Net capex (INR Cr; computed as OCF minus FCF; negative = net disposals) | 0.12 | 0.20 | 1.00 | 0.10 | -0.61 |
Free cash flow (INR Cr; Screener) | -0.02 | -0.82 | -0.69 | -0.87 | -2.50 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%; computed) | 4.1 | 4.7 | 4.5 | 0.7 | -31.6 |
ROA on average assets (%; computed) | 3.2 | 4.4 | 4.1 | 0.6 | -29.3 |
ROCE (%; Screener) | 6.50 | 7.18 | 5.56 | 1.97 | -20.63 |
Debt / equity (x; computed) | 0.005 | 0.002 | 0.037 | 0.115 | 0.002 |
Interest coverage, EBIT / interest (x; computed) | 4.2 | 8.0 | 33.0 | 2.6 | -37.4 |
Asset turnover, sales / average assets (x; computed) | 0.90 | 0.76 | 0.76 | 0.58 | 0.18 |
Debtor days (Screener) | 44.81 | 42.47 | 60.21 | 76.88 | 62.39 |
Inventory days (Screener) | 276.41 | 282.96 | 251.80 | 241.37 | 284.15 |
Payable days (Screener) | 26.58 | 13.39 | 71.61 | 5.89 | 9.24 |
Cash conversion cycle (days; Screener) | 294.64 | 312.03 | 240.40 | 312.37 | 337.30 |
Working capital days (Screener) | 177.04 | 250.75 | 165.57 | 191.82 | 1,553.59 |
Revenue by Region and Revenue by Region (%)
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India revenue (INR Cr) | 4.85 | 4.70 | 1.17 |
Outside India revenue (INR Cr) | 0 | 0 | 0 |
India share of total (%) | 100 | 100 | 100 |
Capital Markets
| Metric | 1-year | 3-year CAGR | 5-year CAGR | 10-year CAGR |
|---|---|---|---|---|
Share price return (%; Screener.in, October 2026) | 78 | 18 | 9 | 13 |
Share price return (%; IIFL, 10 August 2026) | 66.99 | 18.36 | 3.84 | — |
Price Point Details
| Price point | Date | Price (INR) | Source |
|---|---|---|---|
Close | 26 Dec 2024 | 24.45 | Business Standard |
Close | 7 May 2025 | 23.89 | Simply Wall St |
Close | 11 Jul 2025 | 20.25 | IIFL |
Close | 8 Aug 2025 | 29.89 | Trendlyne |
Close | 4 May 2026 | 45.28 | Value Research |
Close | 13 Jul 2026 | 49.91 | Business Today |
Close | 10 Aug 2026 | 52.40 | IIFL |
Close | 19 Oct 2026 | 55.00 | Screener.in |
Open offer price | Feb–May 2026 | 33.00 | SAST filings |
Valuation Multiples
| Multiple | AVI Products | Comment |
|---|---|---|
P/B | 3.53x | Book value per share ₹15.6 |
EV/Sales (TTM) | ~30x | Enterprise value ≈ ₹18.2 crore against TTM sales of ₹0.60 crore. MarketInOut shows 28.95x. |
Peer reference: Vasa Denticity P/E | 64.36x | As of 1 December 2025 (Kotak Securities) |
Peer reference: Vasa Denticity P/B | 6.08x | As of 1 December 2025 (Kotak Securities) |
Balance Sheet — Dividend per share
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Dividend payout (%) | 0 | 0 | 0 | 0 | 0 |
Buyback (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Paid-up equity capital (INR Cr) | 2.58 | 2.58 | 3.31 | 3.31 | 3.31 |
Margin Analysis (%) (Mar-2017–Sep-2026)
| Metric | Mar-2017 | Mar-2020 | Mar-2023 | Mar-2025 | Sep-2026 |
|---|---|---|---|---|---|
Number of shareholders | 13,954 | 13,825 | 13,998 | 14,108 | 13,785 |
Promoter holding (%) | 24.90 | 24.90 | 23.91 | 23.68 | 62.83 |
Analyst Conclusions
Management guidance and consensus
There is no quantitative guidance and no consensus. The only forward-looking statements are the object-clause change to real estate effective FY2027 and the related-party and borrowing frameworks approved in May 2026.
Bull case
-
A clean shell with a motivated, domain-expert promoter. PPMS paid to acquire control, did not seek a delisting, and installed an MD with more than 18 years of SRA and joint-venture experience. A modest redevelopment project or consultancy mandate routed into AVI could generate revenue many times the legacy peak of ₹4.85 crore.
-
Balance-sheet optionality. Debt is near zero and ₹100 crore of borrowing and investment headroom is approved. Combined with residual current assets of about ₹5 crore (if realisable), the listed company can absorb projects quickly.
-
The cost base has been reset. Quarterly expenses fell from ₹102 lakh to ₹28 lakh year on year (Q1 FY2027), so the cash burn of the legacy business has largely stopped. Any new revenue would flow more directly to profit.
Bear case
-
There is no business today. Operating revenue is zero and cash was ₹3.37 lakh. The ₹18 crore market capitalisation (3.53x book) prices in a successful pivot that has not been evidenced by a single announced project.
-
Related-party and governance risk dominates. The approved related-party ceilings total up to ₹1,125 crore across 45 promoter-linked entities. Assets are being sold to outgoing insiders, minority voter participation is about 0.5%, and the board is controller-dominated with CMD duality. Minority shareholders bear asymmetric risk.
-
Dilution is likely. Any real-estate entry will need equity well above ₹5 crore of net worth, most plausibly through preferential issues to the promoter at prices the minority does not control. Combined with surveillance-category status and thin liquidity, this exposes minorities to sharp drawdowns.
Key catalysts and monitorables (next 12 months)
-
Q2 FY2027 results, due after the trading window that closed on 1 October 2026. Watch for:
-
any operating revenue,
-
the composition of the ₹3.6 crore of other current assets,
-
the cash position.
-
-
Related-party transactions under the 45-entity framework. Watch quarterly Regulation 23 disclosures: counterparties, pricing, valuations.
-
Fund-raising. Watch for preferential issues or warrants to the promoter, and for use of the ₹100 crore borrowing limit.
-
First real-estate mandate or project. Watch for RERA registrations, joint development agreements, SRA approvals and consultancy contracts.
-
Completion and pricing of the asset sale to the outgoing promoters and director approved at the 37th AGM.
-
Name change. A rebranding away from "AVI Products" would signal commitment to the pivot.
-
Auditor clarity. Watch for confirmation of the statutory auditor's identity and any qualified opinions.
-
Surveillance status. Watch for GSM/ASM inclusion and exclusion and for any exchange queries on price movements.
Analyst verdict
AVI Products India Limited no longer exists as an operating business in any economically meaningful sense. For three decades it was a family-run micro-trader. It did eventually build a direct-to-dentist e-commerce niche and a small ice-cream franchise, but it never achieved the scale to earn returns above its cost of capital. Peak revenue was ₹4.85 crore, ROCE peaked at 7%, inventory sat on the shelf for more than 240 days, and free cash flow was negative every year from FY2022 to FY2026. The founding family exited at ₹33 per share in April 2026. Before that, the businesses were run down to zero operating revenue, and the remaining assets are now being sold to the departing insiders.
What investors now own is a listed corporate vehicle controlled by PPMS Real Estates LLP. It has a clean debt profile, a ₹100 crore borrowing mandate, a broad object clause and a related-party framework that allows extensive dealings with promoter entities. The promoter's real-estate credentials are relevant and the vehicle carries genuine option value. But the current valuation of ₹55 per share, 3.5x book and about 30x trailing sales, already capitalises a great deal of that option. This is despite no project, contract or capital plan having been disclosed. Cash at FY2026 was effectively nil, and nearly 70% of assets sit in an undisclosed "other current assets" bucket.
For institutional investors, AVI is uninvestable on fundamentals in its present state. It should be treated as a special situation with binary outcomes:
-
substantial value creation, if the promoter injects profitable real-estate activity on fair terms,
-
or material minority value leakage, if related-party, dilution and governance risks materialise.
We would require three things before taking any constructive view:
-
full disclosure of the ₹3.6 crore of other current assets,
-
an announced, arm's-length first project with independent valuation,
-
clarity on capital-raising terms.
Until then, the appropriate stance is avoid / monitor.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Appointed / tenure | Background |
|---|---|---|---|
Parthh Kaushik Mehta | Chairman & Managing Director | Executive Director & Chairman from 23 Apr 2026; MD for 5 years from 5 Aug 2026 (approved at 37th AGM) | More than 18 years in real-estate strategy, valuation and business development. Former CEO of a Mumbai-based real-estate firm. Experienced in Slum Rehabilitation Authority projects and joint ventures. Alumnus of S.P. Jain Centre of Management. Partner in PPMS Real Estates LLP. |
Ameya Vivek Tandulkar | Executive Director | 23 Apr 2026 to 22 Apr 2031 | Business partner of Parthh Mehta in PPMS Real Estates LLP; partner or director in related entities |
Bankim Pranjivan Mehta | Non-Executive Director | 23 Apr 2026 to 22 Apr 2031 | — |
Malvika Jagani | Independent Director | 23 Apr 2026 to 22 Apr 2031 | — |
Dayashankar Patel | Independent Director | 23 Apr 2026 to 22 Apr 2031 | — |
Aditya Soni | Independent Director | 23 Apr 2026 to 22 Apr 2031 | — |
Avinash Dhirajlal Vora (DIN 02454059) | Executive Non-Independent Director | Founder. Chairman & MD for about 36 years until he stepped down as MD on 5 Aug 2026. Redesignated for a 5-year term. | Founder of the company; father of director Vikaram Vora |
Vikaram Vora (DIN 02454043, per FY2026 AGM notice listing) | Director | Long-tenured; current status after the April 2026 resignations is unconfirmed | Son of Avinash Vora |
Manas Ranjan Palo (DIN 01933994) | Independent Director | Appointed 16 Jan 2026 for a term to 15 Jan 2031; current status unconfirmed | — |
Saroj Kumar Choudhury (DIN 11143083) | Non-Executive Non-Independent Director | Appointed 16 Jan 2026; current status unconfirmed. Sold shares to PPMS under the SSPC. | — |
Chief Financial Officer | — | New CFO appointed 23 Apr 2026; name not available in sources reviewed | — |
Company Secretary & Compliance Officer | — | Shanu Jain (ACS A42408) appointed 16 Jan 2026. A new CS was reported appointed on 23 Apr 2026; the name is not available in sources reviewed. | — |
“—” = not publicly disclosed.
Executive Leadership Team
| Executive | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Avinash D. Vora, CMD — total compensation (INR Mn) | 1 | 1 | 1 | 2 | 1.8 |
Shareholding Trend
| Holder category | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | Mar-2026 | Jun-2026 | Sep-2026 |
|---|---|---|---|---|---|---|---|---|
Promoters (%) | 23.68 | 23.68 | 23.68 | 23.68 | 23.68 | 23.68 | 62.83 | 62.83 |
Public (%) | 76.32 | 76.32 | 76.32 | 76.33 | 76.31 | 76.31 | 37.16 | 37.17 |
Number of shareholders | 14,089 | 14,108 | 14,089 | 14,005 | 13,928 | 13,861 | 13,821 | 13,785 |
Major Shareholders
| Holder | Shares | % | Notes |
|---|---|---|---|
PPMS Real Estates LLP (promoter) | 20,77,683 | 62.83 | Built up as follows: 8,19,868 in market purchases (Feb 2026), 7,83,091 under the SPA, 4,69,710 under the SSPC, and 5,014 through the open offer |
Institutional investors (MF/FII/insurance) | — | ~0 | No institutional holdings reported in the sources reviewed |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| Competitor | Type | Scale indicator | Relative positioning vs AVI |
|---|---|---|---|
Vasa Denticity Ltd (Dentalkart.com) | NSE-listed dental e-commerce leader | FY2025 sales ₹249.37 crore, net profit ₹16.97 crore, OPM 9.19% (Capital Market, May 2025) | Over 50x AVI's peak revenue; national logistics, private labels, about 335,000 monthly active users (H1 FY2025) |
Pinkblue.in | Private dental e-commerce platform | — | Larger online catalogue and VC-backed |
Dentganga | Private dental e-commerce platform | — | Direct online competitor |
Dental Mantra / Oralkart and similar online sellers | Private online dental retailers | — | Fragmented long tail |
Dentsply Sirona (India operations) | Global manufacturer with direct and distributor sales | — | Brand owner; AVI sells adjacent product categories |
3M / Solventum Oral Care (India) | Global manufacturer | — | Premium consumables brand |
Prevest DenPro Ltd | NSE-listed Indian dental-materials manufacturer | — | Manufacturer of consumables (composites, endodontic materials) that competes with traded SKUs |
Local dental dealers (offline) | Fragmented regional distributors | Not quantifiable | Relationship-based; AVI's digital model sought to bypass them |
Key Competitors — Natural Ice Cream
| Competitor | Type | Positioning vs IFRUIT |
|---|---|---|
Natural Ice Cream (Kamath Ourfoods) | Private premium parlour chain | Far larger brand and network |
Baskin-Robbins (Graviss Foods, India master franchisee) | Franchise chain | National franchise network |
Havmor (Lotte) | Multinational-owned ice-cream brand and parlours | Mass-market scale |
Amul | Cooperative mass-market ice cream | Price leader |
Kwality Wall's (Hindustan Unilever / successor) | FMCG ice cream | Distribution scale |
Belgian Waffle Co. | Franchise dessert QSR | Direct overlap on waffles |
Rolled ice-cream kiosks (unbranded) | Local operators | Direct overlap on rolled ice-cream |
Peer Comparison FY2026
| Metric | AVI Products (FY2025) | AVI Products (FY2026) | Vasa Denticity (FY2025) |
|---|---|---|---|
Revenue (INR Cr) | 4.70 | 1.17 | 249.37 |
Revenue growth YoY (%) | -3.1 | -75.1 | 46.9 |
Operating margin (%) | 0.85 | -126.50 | 9.19 |
Net profit (INR Cr) | 0.05 | -1.94 | 16.97 |
R&D intensity (%) | 0 | 0 | — |
“—” = not publicly disclosed.



